SEC Form 4 · accession 0001193125-26-386508
NewAmsterdam Pharma Co N.V. · NAMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Smither
Director
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001936258
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F3 | Sep 4, 2026 | S | 1,600 | $25.32 | D | 8,760 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F3Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.